Ireland-headquartered drugmaker Shire (LSE: SHP) says it is on track to achieve double-d digit growth for the full year 2012, as it posted second-quarter financial results, with total revenues up 14% at $1.21 billion and product sales rising 16% to $1.14 billion.
Non-GAPP operating income leapt 23% to $420 million and GAPP operating income advanced 7% to $302 million, with diluted earnings per ADR rising 26% to $1.68 and 15% to $1.24, respectively. Shares of Shire, the UK’s third-largest drugmaker, rose 5.4% to £19.47 by mid afternoon yesterday.
Angus Russell, chief executive, commented: “Shire delivered strong results in the second quarter, with product sales up 16% and Non GAAP operating income up 23%. The ADHD [attention-deficit hyperactivity disorder] market in the USA is maintaining healthy growth; our lead products Vyvanse [lisdexamfetamine] and Intuniv [guanfacine] both increased share and we’re advancing our plans for the continued international rollout of both these products. Although of decreasing importance in our ADHD portfolio, we believe that branded Adderall XR [mixed amphetamine salts] will remain competitive in the US marketplace despite the approval of a new generic product.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze